Frontage Laboratories Inc., a Malvern, Pa.-based contract research organization for pharma and biotech companies, has raised $10 million in growth equity funding led by Baird Capital Partners
Baird Capital Partners Asia (BCPA), the Greater China-focused investment group of Baird Private Equity, announced today it has completed its first investment, providing $10 million of growth equity capital along with other investors to Frontage Laboratories, Inc. (Frontage). Frontage is a leading
Frontage assists its clients with resolving complex product development issues and advancing drug candidates through preclinical and clinical development stages to commercialization, drawing on its expertise in pharmaceutical analysis; bioanalytical research and testing formulation development; custom synthesis of investigational compounds; and clinical materials manufacturing and packaging.
Frontage's experienced management team and talented scientific staff have made significant contributions to large and emerging pharmaceutical companies in drug discovery research, development and commercialization. In 2007, this team's accomplishments and the Company's stable growth earned Frontage a ranking as one of the top 20 fastest growing companies in the Greater Philadelphia area on the “Philadelphia 100” list published annually by the Philadelphia Business Journal. Today, Frontage serves four of the top ten largest pharmaceutical companies in the world.
“Our capabilities in
“When looking for a private equity partner, we knew we needed an investor that understood both the Chinese and
BCPA provides growth equity capital to smaller, high-potential companies that have substantial operations and growth opportunities in Greater China. Leveraging Baird's global capabilities focused on the smaller end of the middle market, BCPA invests in companies domiciled both in and outside of Greater China. BCPA also is supported by Baird Private Equity's team of more than 20 operating professionals in
“Frontage is the perfect type of business that we are looking to partner with through our Asian investment group,” said Brett Tucker, BCPA Partner. “Our operating capabilities and capital will allow Frontage to finance its growth in
“Dr. Song Li and the Frontage team have built an impressive, customer focused organization that serves customers in the
Brett Tucker and Gregg Fergus will join the Frontage board of directors as part of this transaction.
Pavilion Capital Partners, existing individual shareholders and members of management also invested in the transaction.
About Frontage Laboratories, Inc. Frontage Laboratories, Inc. is a rapidly expanding pharmaceutical R&D services company located in the greater
About Baird Capital Partners Asia Baird Capital Partners Asia, the China-focused investment group of Baird Private Equity, provides growth equity capital to smaller, high-potential companies with substantial operations and growth opportunities in Greater China. Baird Capital Partners Asia leverages its in-depth sector knowledge, experienced investment team and extensive operating resources to drive value in its portfolio companies. Baird Capital Partners Asia has representative offices in Hong Kong, Beijing, and Shanghai, and invests in three industry sectors: manufactured products, business services and healthcare. For more information, please visit www.bairdcapitalpartnersasia.com <http://www.bairdprivateequity.com/private-equity/baird-capital-partners -asia.aspx> .
About Baird Private Equity Baird Private Equity, the global private equity group affiliated with Robert W. Baird & Co. (Baird), makes venture capital, growth equity and buyout investments in smaller, high potential companies in the United States through Baird Venture Partners and Baird Capital Partners, in Greater China through Baird Capital Partners Asia, and in Europe through Baird Capital Partners Europe and Granville Baird, an affiliated fund manager that invests in Germany. Baird Private Equity has a global team of 80 professionals in nine offices across the United States, Europe and Asia, including over 20 operating professionals in Asia. Baird Private Equity and its affiliates have raised and managed approximately $2.4 billion in capital and invested in over 220 companies since the 1980s. For more information, please visit www.bairdprivateequity.com